Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

SURMOUNT-1

Eli Lilly · Phase 3 · Completed · Enrollment 2539

NCT04184622

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

34.590.9
≥5%
≥10%
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Placebo34.5%n/rn/rn/r
5 mg Tirzepatiden/rn/rn/rn/r
10 mg Tirzepatiden/rn/rn/rn/r
15 mg Tirzepatide90.9%n/rn/rn/r

Not shown

  • 5 mg Tirzepatide: endpoint not reported
  • 10 mg Tirzepatide: endpoint not reported